Racial and Social Economic Factors Impact on the Cause Specific Survival of Pancreatic Cancer: A SEER Survey

  • Published : 2013.01.31


Background: This study used Surveillance, Epidemiology and End Results (SEER) pancreatic cancer data to identify predictive models and potential socio-economic disparities in pancreatic cancer outcome. Materials and Methods: For risk modeling, Kaplan Meier method was used for cause specific survival analysis. The Kolmogorov-Smirnov's test was used to compare survival curves. The Cox proportional hazard method was applied for multivariate analysis. The area under the ROC curve was computed for predictors of absolute risk of death, optimized to improve efficiency. Results: This study included 58,747 patients. The mean follow up time (S.D.) was 7.6 (10.6) months. SEER stage and grade were strongly predictive univariates. Sex, race, and three socio-economic factors (county level family income, rural-urban residence status, and county level education attainment) were independent multivariate predictors. Racial and socio-economic factors were associated with about 2% difference in absolute cause specific survival. Conclusions: This study s found significant effects of socio-economic factors on pancreas cancer outcome. These data may generate hypotheses for trials to eliminate these outcome disparities.


  1. Kuhn Y, Koscielny A, Glowka T, et al (2010). Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status. Eur J Surg Oncol, 36, 496-500.
  2. Ludwig J, Sanbonmatsu L, Gennetian L, et al (2011). Neighborhoods, obesity, and diabetes--a randomized social experiment. N Engl J Med, 365, 1509-19.
  3. Neoptolemos JP, Moore MJ, Cox TF, et al (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308, 147-56.
  4. Regine WF, Winter KA, Abrams RA, et al (2008). Fluorouracil vs gemcitabine chemotherapy before and after fluorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA, 299, 1019-26.
  5. Singal V, Singal AK, Kuo YF (2012). Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol, 138, 715-22.
  6. Strimpakos AS, Syearsigos KN, Saif MW (2012). Translational research. New findings and potential future applications in pancreatic adenocarcinoma. JOP, 13, 177-9.
  7. Tokh M, Bathini V, Saif MW (2012). First-line treatment of metastatic pancreatic cancer. JOP, 13, 159-62.
  8. van Loon AJ, Brug J, Goldbohm RA, et al (1995). Differences in cancer incidence and mortality among socio-economic groups. Scand J Soc Med, 23, 110-20.
  9. van Oost FJ, Luiten EJ, van de Poll-Franse LV, et al (2006). Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol, 32, 548-52.
  10. Worni M, Akushevich I, Gloor B, et al (2012). Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. Ann Surg Oncol, 19, 1316-23.
  11. Baine M, Sahak F, Lin C, et al (2011). Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One, 6, 21052.
  12. Brown J, Harding S, Bethune A, Rosato M (1998). Longitudinal study of socio-economic differences in the incidence of stomach, colorectal and pancreatic cancers. Popul Trends, 94, 35-41.
  13. Cheung R (2012). Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: a us SEER data analysis. Asian Pac J Cancer Prev, 13, 4587-91.
  14. Franko J, Puri DR, Goldman CD (2012). Impact of radiation therapy sequence on survival among patients with resected pancreatic head ductal carcinoma. Ann Surg Oncol, 19, 26-30.
  15. Gill AJ, Martin IG (2002). Survival from upper gastrointestinal cancer in New Zealand: the effect of distance from a major hospital, socio-economic status, ethnicity, age and gender. ANZ J Surg, 72, 643-6.

Cited by

  1. Receiver Operating Characteristic Curve Analysis of SEER Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) Outcome Data: Identification and Optimization of Predictive Models vol.15, pp.16, 2014,
  2. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer vol.15, pp.17, 2014,
  3. Effects of Secondary Left-sided Portal Hypertension on the Radical Operation Rate and Prognosis in Patients with Pancreatic Cancer vol.15, pp.5, 2014,
  4. The Impact of Demographic and Socioeconomic Factors on Major Salivary Gland Cancer Survival vol.150, pp.6, 2014,
  5. Epidemiologic Data, Tumor Size, Histologic Tumor Type and Grade, Pathologic Staging and Follow Up in Cancers of the Ampullary Region and Head of Pancreas in 311 Whipple Resection Specimens of Pakistani Patients vol.16, pp.17, 2015,
  6. Racial Disparities in Extremity Soft-Tissue Sarcoma Outcomes vol.38, pp.6, 2015,
  7. The Impact of Socioeconomic Status, Surgical Resection and Type of Hospital on Survival in Patients with Pancreatic Cancer. A Population-Based Study in The Netherlands vol.11, pp.11, 2016,
  8. Identifying Factors Influencing Pancreatic Cancer Management to Inform Quality Improvement Efforts and Future Research vol.45, pp.2, 2016,
  9. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis vol.11, pp.7, 2017,
  10. Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma pp.14783223, 2017,
  11. Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial vol.142, pp.12, 2018,
  12. Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities vol.18, pp.1, 2018,